Table 2.
Performance of DAST compared with reference AST method for Enterobacterales by VITEK-2 system
Enterobacterales (60) | Categorical agreement, n (%) | Categorical disagreement n (%) | Essential agreement | ||||
---|---|---|---|---|---|---|---|
Minor error | Major error | Very major error | Total | Agreed | Disagreed | ||
Cefoperazone sulbactam | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Amoxicillin/clavulanic acid | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Piperacillin/tazobactam | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Cefuroxime | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Cefuroxime axetil | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Cefepime | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Ceftriaxone | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Imipenem | 54 (90.0%) | 2 (3.3%) | 4 (6.7%) | 0 (0.0%) | 6 (10.0%) | 57 (95%) | 3 (5.0%) |
Meropenem | 59 (98.3%) | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) | 1 (1.7%) | 58 (96.7%) | 2 (3.3%) |
Amikacin | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Gentamicin | 59 (98.3%) | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) | 1 (1.7%) | 58 (96.7%) | 2 (3.3%) |
Ciprofloxacin | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
Tigecycline | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100.0%) | 0 (0.0%) |
Colistin | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100.0%) | 0 (0.0%) |
Cotrimoxazole | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100.0%) | 0 (0.0%) |